Inovio Pharmaceuticals Inc (NASDAQ: INO) kicked off on Tuesday, down -3.72% from the previous trading day, before settling in for the closing price of $1.88. Over the past 52 weeks, INO has traded in a range of $1.74-$14.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 63.34%. While this was happening, its average annual earnings per share was recorded 34.50%. With a float of $36.41 million, this company’s outstanding shares have now reached $36.67 million.
Let’s determine the extent of company efficiency that accounts for 134 employees. In terms of profitability, gross margin is -629.42%, operating margin of -51616.91%, and the pretax margin is -11594429.84%.
Inovio Pharmaceuticals Inc (INO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Inovio Pharmaceuticals Inc is 0.69%, while institutional ownership is 36.51%.
Inovio Pharmaceuticals Inc (INO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.75% during the next five years compared to 22.92% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Take a look at Inovio Pharmaceuticals Inc’s (INO) current performance indicators. Last quarter, stock had a quick ratio of 2.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 301.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.98, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.23 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Looking closely at Inovio Pharmaceuticals Inc (NASDAQ: INO), its last 5-days average volume was 1.15 million, which is a jump from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 9.25%. Additionally, its Average True Range was 0.13.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 1.72%, which indicates a significant decrease from 9.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.53% in the past 14 days, which was lower than the 102.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0296, while its 200-day Moving Average is $5.3234. However, in the short run, Inovio Pharmaceuticals Inc’s stock first resistance to watch stands at $1.8900. Second resistance stands at $1.9700. The third major resistance level sits at $2.0300. If the price goes on to break the first support level at $1.7500, it is likely to go to the next support level at $1.6900. Should the price break the second support level, the third support level stands at $1.6100.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
The company with the Market Capitalisation of 66.37 million has total of 26,100K Shares Outstanding. Its annual sales at the moment are 220 K in contrast with the sum of -107,250 K annual income. Company’s last quarter sales were recorded 120 K and last quarter income was -19,380 K.
